Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967957 | 0.82 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3286812 | 0.80 | CHRM2 (0.38) | CYP3A4SMN1; SMN2 | |
| SCHEMBL29823262 | 0.80 | DUT (0.35) | SIGMAR1FDPS | |
| SCHEMBL1474688 | 0.80 | DUT (0.35) | SIGMAR1FDPS | |
| SCHEMBL6617538 | 0.79 | MAOB (0.49) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3945475 | 0.78 | EGFR (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL453430 | 0.77 | SMN1; SMN2 (0.44) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL28723954 | 0.77 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL28983356 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL21176568 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562060-B2 | Heterocyclic pyridone compound, and intermediate, preparation method and use thereof | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2017-02-07 | — | — | US | disclosed |
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD (CN) | 2014-07-24 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | SMYD2 1533/4885CYP3A4 2690/4885HTT 4647/4885 |
| US-20140206679-A1 | HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | MET, PDXK, FLT3 | SMYD2 3514/4885CYP3A4 206/4885HTT 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.